Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDX-1097 phase II study in previously treated kappa light-chain restricted multiple myeloma
ACTRN12610000700033Phase 2Recruiting
- Sponsor
- Immune System Therapeutics
- Start
- Jul 2010
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MDX-1097 in multiple myeloma (MM), sponsored by Immune System Therapeutics. Primary endpoint: Efficacy of MDX-1097. Started Jul 2010; status: recruiting.
02
Drugs
MDX-1097
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12610000700033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000700033.